Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics reported 52-week topline results from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. In a 16-week blinded extension to week 52, 29% of patients on the 18 µg/kg dose and 31% on the 24 µg/kg dose achieved new SALT Score ≤20 responses, meaning at least 80% scalp hair coverage, versus none on placebo. For the overall study population at week 52, 25.8% on low dose and 27.6% on high dose reached SALT ≤20 compared with 6.7% on placebo, and 30.2% and 35.0% reached SALT ≤30 versus 8.4% on placebo. Clinically meaningful improvements (SALT50 and SALT30) were also higher with rezpegaldesleukin, and 94% of patients in the extension completed 52 weeks. Safety remained favorable, with nearly all adverse events mild to moderate, low discontinuation due to adverse events, and mainly transient injection site reactions. The company states that these data support advancing rezpegaldesleukin into late-stage development in alopecia areata.
Nektar Therapeutics reported 52-week topline results from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. In a 16-week blinded extension to week 52, 29% of patients on the 18 µg/kg dose and 31% on the 24 µg/kg dose achieved new SALT Score ≤20 responses, meaning at least 80% scalp hair coverage, versus none on placebo. For the overall study population at week 52, 25.8% on low dose and 27.6% on high dose reached SALT ≤20 compared with 6.7% on placebo, and 30.2% and 35.0% reached SALT ≤30 versus 8.4% on placebo. Clinically meaningful improvements (SALT50 and SALT30) were also higher with rezpegaldesleukin, and 94% of patients in the extension completed 52 weeks. Safety remained favorable, with nearly all adverse events mild to moderate, low discontinuation due to adverse events, and mainly transient injection site reactions. The company states that these data support advancing rezpegaldesleukin into late-stage development in alopecia areata.
Nektar Therapeutics Schedule 13G shows Two Seas Capital and related filers report beneficial ownership of 1,959,178 shares of Common Stock, equal to 6.8% of the class. The stake is held by Two Seas Global (Master) Fund LP and reported with voting and dispositive power held solely by the reporting entities.
The percentage is calculated using 28,687,963 shares outstanding as of March 11, 2026, per the issuer's Form 10-K; filings are signed by Sina Toussi on behalf of the reporting parties.
The Vanguard Group filed an amendment to a Schedule 13G/A reporting 0% beneficial ownership of Nektar Therapeutics common stock. The filing states Vanguard completed an internal realignment effective January 12, 2026, after which certain subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The amendment is signed on 03/27/2026.
Filer submitted a Form 144 notice to sell Common Stock on 03/13/2026. The filing lists proposed cash sales of Common shares tied to stock option exercises: 28,848, 44,250, and 5,412 shares, each dated 03/13/2026.
The broker listed is Fidelity Brokerage Services LLC. The excerpt shows a dollar figure $5,702,966.40 and a numeric entry 28,687,963, both included verbatim in the excerpt.
Nektar Therapeutics is a clinical-stage biopharma focused on immunotherapy for autoimmune disease and cancer. Its lead asset, rezpegaldesleukin, targets IL‑2 receptors to expand regulatory T cells and is in Phase 2b trials for atopic dermatitis and alopecia areata, with FDA Fast Track designations for both indications.
In the REZOLVE‑AD study, rezpegaldesleukin achieved statistically significant improvements in standard eczema scores and itch at 16 weeks and showed durable responses out to 52 weeks with favorable tolerability, mainly mild injection site reactions. REZOLVE‑AA topline data showed meaningful hair regrowth trends and supportive safety, with statistical significance when four ineligible patients were excluded.
The pipeline also includes preclinical TNFR2 agonist antibodies NKTR‑0165 and NKTR‑0166 for autoimmune disease, oncology candidate NKTR‑255 targeting IL‑15 in combination studies, and preclinical PEG‑CSF1 program NKTR‑422. Nektar reported research and development expense of $117,330 (in thousands) for 2025 and remains dependent on future partnerships and sufficient capital to advance its programs.
Nektar Therapeutics reported weaker 2025 results alongside a significantly stronger cash position after recent financings. Revenue for 2025 was $55.2 million compared to $98.4 million in 2024, mainly because product sales ended after the December 2024 sale of the Huntsville manufacturing facility and non-cash royalty revenue declined.
Total operating costs and expenses were $195.3 million versus $203.6 million in 2024, reflecting lower cost of goods sold and reduced R&D and G&A spending, partially offset by restructuring and impairment charges linked to San Francisco real estate and an equity-method loss from Gannet BioChem. Net loss widened to $164.1 million, or $9.73 per share, from $119.0 million, or $8.68 per share, while non-GAAP net loss excluding the equity investment loss and restructuring was $146.0 million, or $8.66 per share.
Cash and investments in marketable securities were $245.8 million as of December 31, 2025, versus $269.1 million a year earlier, and this balance excludes approximately $432 million of net proceeds from a $460 million secondary offering and $44 million of net proceeds from at-the-market share sales completed in early 2026. Management highlighted positive Phase 2 data for lead autoimmune candidate rezpegaldesleukin and plans to initiate a Phase 3 atopic dermatitis program in June 2026 while advancing additional immunology and oncology pipeline assets.
Nektar Therapeutics reports that FMR LLC beneficially owns 3,036,760.61 shares of common stock, representing 11.1% of the class as reported on 02/27/2026. The filing is a Schedule 13G disclosing ownership and states Abigail P. Johnson holds dispositive power over the same 3,036,760.61 shares. The filing references an agreement in Exhibit 99 and is signed by an authorized representative of FMR LLC.
NEKTAR THERAPEUTICS Chief R&D Officer Jonathan Zalevsky sold 180 shares of common stock on February 18, 2026 to cover required tax withholding obligations tied to vesting RSUs, and this was not a discretionary trade. The weighted average sale price was $73.00 per share, and he held 21,174 shares directly after the transaction.
Nektar Therapeutics President & CEO Robin Howard W reported an open-market sale of 423 shares of common stock on February 18, 2026 at a weighted average price of $73.00 per share. According to the disclosure, these shares were sold to cover required tax withholding obligations related to vesting restricted stock units, and the filing notes this was not a discretionary trade. After the transaction, he directly held 75,489 shares of common stock, with an additional 28 shares held indirectly by his spouse.
Form 144 filing reports insider share sales and planned sales. The filing lists 423 common shares marked under "Securities To Be Sold" tied to Restricted Stock Vesting on 02/13/2026, and shows 2,207 common shares sold on 11/25/2025.